-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Xetra FrankfurtEURISIN US02043Q1076-
Alnylam PharmaceuticalsBörse Xetra FrankfurtISIN US02043Q1076EURSymbol DUL
-
Alnylam PharmaceuticalsBörse Börse FrankfurtEURSymbol DUL
-
Alnylam PharmaceuticalsBörse Börse MünchenEURSymbol DUL
-
ALNYLAM PHARMACEUTICALS INCBörse Börse HamburgEURSymbol DUL
-
ALNYLAM PHARMACEUTICALS INCBörse Börse StuttgartEURSymbol DUL
-
ALNYLAM PHARMACEUTICALS INCBörse Quotrix System der Börse DüsseldorfEURSymbol DUL
-
ALNYLAM PHARMACEUTICALS INCBörse Börse BerlinEURSymbol DUL
-
ALNYLAM PHARMACEUTICALS INCBörse Gettex System der Börse MünchenEURSymbol DUL
-
ALNYLAM PHARMACEUTICALS INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol DUL
-
ALNYLAM PHARMACEUTICALS INCBörse Börse DüsseldorfEURSymbol DUL
-
ISIN US02043Q1076 WKN: A0CBCKSymbol ALNY
-
Alnylam Pharmaceuticals, Inc.Börse BVMF
-
ISIN US02043Q1076
Symbol DUL
Währung
EUR
Börse
Xetra Frankfurt Zeitzone: Europe/Berlin
Firmenname
Alnylam Pharmaceuticals, Inc
Marktkapitalisierung
17.921.151.456 (+- 2%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
18.347.302.912 oder 17.495.000.000
Mitarbeiter
1.663 (+- 20%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
1.323 oder 2.002 Mitarbeiter
EBITDA -877.000.000
PEGRatio -0.49
Buchwert 10.461
Alnylam Pharmaceuticals underperformed den DAX um -51 % vom 04.10.2013 bis 17.10.2017
Entdecke die 6 ETFs in denen Alnylam Pharmaceuticals, Inc am höchsten gewichtet ist Insgesamt in 33 ETFs enthalten
Dir gefallen die Informationen zu Alnylam Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Alnylam Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Alnylam Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Alnylam Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
39 News & Informationen zur Alnylam Pharmaceuticals Aktie
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 175 companies set new 52-week highs.
Key Facts: Nike (NYSE:NKE) was the biggest company by market cap to set a …
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q2 2021 Results – Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. Q2 2021 Earnings Conference Call Aug 3, 2021 8:30 AM ET Company Participants Christine Lindenboom – Investor Relations John Maraganore – Chief Executive…
Alnylam Pharmaceuticals, Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:ALNY)
The following slide deck was published by Alnylam Pharmaceuticals, Inc.
Alnylam Pharma Increases 2021 Combined Net Product Revenues Guidance
(RTTNews) – Alnylam Pharmaceuticals, Inc. (ALNY) said the company is increasing its revenue guidance for 2021, and now expects to achieve between …
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis …
PeptiDream : Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Ti
− Agreement Combines PeptiDream’s Peptide Discovery Platform to Identify High Affinity Peptide Ligands with Alnylam’s Expertise in siRNA-Conjugate-Based Delivery and in Developing… | July 29, 2021
Dicerna Announces FDA Clearance Of Investigational New Drug (IND) Application For DCR-AUD For The Treatment Of Alcohol Use Disorder
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)
Alnylam Reports Positive Topline Results From ILLUMINATE-C Phase 3 Study Of Lumasiran In Patients With Advanced Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3
Mixed Session as Fed, Earnings Compete For Market’s Attention
Stocks Analysis by Zacks Investment Research covering: Microsoft Corporation, Alphabet Inc Class A, Apple Inc, Amazon.com Inc. Read Zacks Investment Research's latest article on Investing.com
Were Hedge Funds Right About Brookfield Property Partners LP (BPY)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
Dicerna Announces Interim Results From Phase 1 Trial Of Belcesiran For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)
Worldwide RNA Therapeutics Industry – Featuring BioNTech, Moderna Therapeutics And CureVac Among Others
DUBLIN, July 15, 2021 /PRNewswire/ — The
Worldwide RNA Therapeutics Industry – Featuring BioNTech, Moderna Therapeutics and CureVac Among Others
/PRNewswire/ — The
Alnylam Pharmaceuticals Inc (ALNY) EVP, Chief Legal Officer Laurie Keating Sold $1.2 million of Shares
GuruFocus Article or News written by insider and the topic is about:
Cohen Lawrence B Buys BlackRock Inc, Alnylam Pharmaceuticals Inc, Sells T. Rowe Price Group Inc, Colgate-Palmolive Co, Vanguard Health Care ETF
GuruFocus Article or News written by insider and the topic is about:
Hedge Funds Are Buying Genuine Parts Company (GPC)
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms…
State of Alaska, Department of Revenue Buys Alexion Pharmaceuticals Inc, Adobe Inc, ViacomCBS Inc, Sells Qualcomm Inc, Target Corp, Costco Wholesale Corp
GuruFocus Article or News written by insider and the topic is about:
2 Biotech Stocks That are Dirt Cheap Right Now
The biotech industry has received much attention lately for its contribution to the world’s fight against COVID-19. Furthermore, with the help of new…
Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity
Biodefense Market Growth Analysis in Biotechnology Industry | Technavio
/PRNewswire/ — Set to grow by USD 5.41 billion during 2021-2025, Technavio's latest market research report estimates the biodefense market to register a CAGR…
Biodefense Market Growth Analysis in Biotechnology Industry | Technavio
NEW YORK, July 7, 2021 /PRNewswire/ — Set to grow by USD 5.41 billion during 2021-2025, Technavio's latest market research report estimates the b…
Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today
A paused clinical trial with an important asset wasn't what investors wanted to hear today.
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)
Regeneron Pharmaceuticals : Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
TARRYTOWN, N.Y., July 1, 2021 /PRNewswire/ —
Publication in Science reports that people with these protective mutations have 54% reduced risk of obesity
Regeneron used its… | July 1, 2021
What’s Next For Alnylam Stock After The Recent Positive Development For Intellia?
The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a 4.1% drop over the last five trading days, after another pharmaceutical company – Intellia Therapeutics – announced positive findings from…
Alnylam Initiates KARDIA-1 Phase 2 Study Of Zilebesiran (ALN-AGT) In Patients With Mild-to-Moderate Hypertension
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-1, a global Phase 2 study evaluating
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?
Global Gene Therapy Market To Reach $2.7 Billion By 2026
SAN FRANCISCO, June 29, 2021 /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today
Hedge Funds Have Never Been This Bullish On Sun Communities Inc (SUI)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However…
Intellia Shares Soar on Positive Test Results
GuruFocus Article or News written by Barry Cohen and the topic is about: Merck, Sanofi, Gilead and others stand to benefit from clinical trials
Here is What Hedge Funds Think About The Liberty SiriusXM Group (LSXMA)
In this article you are going to find out whether hedge funds think The Liberty SiriusXM Group (NASDAQ:LSXMA) is a good investment right now. We like…
Alnylam To Host Eighth Annual “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 8 th annual series of “RNAi
Alnylam Pharmaceuticals : Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
– Single Doses of Investigational ALN-AGT Achieved Sustained Reductions in Serum Angiotensinogen at 12 Weeks Resulting in Reduced Blood Pressure –
– Durability of AGT Knockdown… | April 11, 2021
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ja…
Alnylam Pharmaceuticals : Launches “ P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
– New 5-Year Strategy Represents Alnylam’s Commitment to Delivering Transformative Rare and Prevalent Disease Medicines for Patients Around the World Through Sustainable Innovation and… | January 10, 2021
Alnylam Launches “Alnylam P5x25” Strategy For Planned Transition To A Top Five Biotech In Market Capitalization Over Next Five Years
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy ” Alnylam P 5×25″ focused on the
ALDX Catches Eye, RVNC Faces Busy Year Ahead, SRPT Plunges On DMD Trial Data
Today's Daily Dose brings you news about Alnylam's transthyretin-mediated (ATTR) amyloidosis trial results; Sarepta's mixed results of investigational gene therapy SRP-9001 in patients with Duchenne muscular dystrophy; Aldeyra's dry eye disease trial results; and Revance's anticipated milestones.
Get Ready For Health Care Stocks to Go Wild. How to Play Them.
Politics is the hot story of January, but health care might be the hot trade.
Dicerna Pharmaceuticals : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Compensation Committee of the Company’s Board of… | January 4, 2021